Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden

References

• Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020 May 19;323(19):1945–1960. doi: 10.1001/jama.2020.4006
   PubMed Web of Science ®Google Scholar
• Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 Study. Front Med. 2021;8:743180. doi: 10.3389/fmed.2021.743180
   PubMed Web of Science ®Google Scholar
• Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016 Nov 24;2(1):16082. doi: 10.1038/nrdp.2016.82
   PubMedGoogle Scholar
• Tildrakizumab. Summary of product characteristics.
   Google Scholar
• Cheng Xu JJ, Su T, Wang H-W, et al. The association of psoriasis and obesity: focusing on IL-17A-Related immunological mechanisms. Int J Dermatol Venereol. 2021;4(2):116–121. doi: 10.1097/JD9.0000000000000155
   Google Scholar
• Thaci D, Gerdes S, Du Jardin KG, et al. Efficacy of tildrakizumab across different body weights in moderate-to-severe psoriasis over 5 years: pooled analyses from the reSURFACE pivotal studies. Dermatol Ther. 2022 Oct;12(10):2325–2341. doi: 10.1007/s13555-022-00793-z
   Web of Science ®Google Scholar
• Pirro F, Caldarola G, Chiricozzi A, et al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021 Oct;41(10):917–925.
   PubMed Web of Science ®Google Scholar
• Schwarz CW, Loft N, Rasmussen MK, et al. Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish nationwide cohort study. Acta Derm Venereol. 2021 Oct 26;101(10):adv00579. doi: 10.2340/actadv.v101.351
   PubMedGoogle Scholar
• Warren RB, Marsden A, Tomenson B, et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019 May;180(5):1069–1076.
   PubMed Web of Science ®Google Scholar
• Assan F, Tubach F, Arlegui H, et al. First-line biologic therapy and obesity in moderate-to-severe psoriasis: results from the prospective multicenter cohort psobioteq. Dermatology. 2021;237(3):338–346. doi: 10.1159/000513398
   PubMed Web of Science ®Google Scholar
• Adalimumab. Summary of product characteristics.
   Google Scholar
• Bimekizumab. Summary of product characteristics.
   Google Scholar
• Certolizumab. Summary of product characteristics.
   Google Scholar
• Secukinumab. Summary of product characteristics.
   Google Scholar
• Ustekinumab. Summary of product characteristics.
   Google Scholar
• Becher G, Conner S, Ingram JA, et al. A retrospective real-world study of the effectiveness and tolerability of Tildrakizumab in UK adults with moderate-to-severe chronic plaque psoriasis. Dermatol Ther. 2022 Oct;12(10):2343–2354.
   Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017 Jul 15;390(10091):276–288. doi: 10.1016/S0140-6736(17)31279-5
   PubMed Web of Science ®Google Scholar
• Thaci D, Piaserico S, Warren RB, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021 Aug;185(2):323–334.
   PubMed Web of Science ®Google Scholar
• Ter Haar ELM, den Reek J V, Du Jardin K G, et al. Efficacy and safety of tildrakizumab in older patients: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 244 weeks. Acta Derm Venereol. 2023 Oct 25;103:adv17752. doi: 10.2340/actadv.v103.17752
   PubMed Web of Science ®Google Scholar
• Fernandez AP, Dauden E, Gerdes S, et al. Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1774–1783.
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Blauvelt A, et al. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. J Eur Acad Dermatol Venereol. 2019 Jun;33(6):1098–1106.
   PubMed Web of Science ®Google Scholar
• Kokolakis G, Kreis G, Falques M, et al. High tolerability, favorable safety, and subjects’ preference for a single 200 mg/2 mL tildrakizumab injection: a phase I, open-label, randomized crossover trial in healthy volunteers. Dermatol Ther. 2022 Sep;12(9):2135–2144. doi: 10.1007/s13555-022-00789-9
   Web of Science ®Google Scholar
• Burlando M, Maul JT, Salvi I, et al. Psoriasis patients’ characteristics associated with high PASI response to tildrakizumab: an international dual center study. Eur Rev Med Pharmacol Sci. 2022 Sep;26(18):6772–6776.
   PubMed Web of Science ®Google Scholar
• Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2023 Jan;37(1):93–103.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, Palmoplantar and genital psoriasis. J Clin Med. 2022 May 7;11(9):2631. doi: 10.3390/jcm11092631
   PubMed Web of Science ®Google Scholar
• Di Brizzi EV, Buononato D, Benvenuto P, et al. Effectiveness and safety after a switch to Tildrakizumab: a real world multicenter Italian study in psoriasis. Dermatol Pract Concept. 2023 Oct 1;13(4):e2023215. doi: 10.5826/dpc.1304a215
   PubMedGoogle Scholar
• Kimball AB, Papp KA, Reich K, et al. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. Br J Dermatol. 2020 Jun;182(6):1359–1368.
   PubMed Web of Science ®Google Scholar
• Queille-Roussel C, Rosen M, Clonier F, et al. Efficacy and safety of calcipotriol plus betamethasone dipropionate aerosol foam compared with betamethasone 17-valerate-medicated plaster for the treatment of psoriasis. Clin Drug Investig. 2017 Apr;37(4):355–361.
   PubMed Web of Science ®Google Scholar
• Naslund-Koch C, Zachariae C, Skov L. Tildrakizumab: an evidence-based review of its use in the treatment of moderate-to-severe chronic plaque psoriasis. Ther Clin Risk Manag. 2020;16:903–916. doi: 10.2147/TCRM.S227880
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020 Mar;182(3):605–617.
   PubMed Web of Science ®Google Scholar
• Shear NH, Betts KA, Soliman AM, et al. Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data. J Am Acad Dermatol. 2021 Sep;85(3):572–581.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Chiricozzi A, Ehst BD, et al. Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review. Adv Ther. 2023 Aug;40(8):3410–3433.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Jullien D, Gaarn Du Jardin K, et al. Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest. J DermatolTreat. 2023 Dec;34(1):2220447. doi: 10.1080/09546634.2023.2220447
   Google Scholar
• Megna M, Fabbrocini G, Ruggiero A, et al. Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12/23 and/or anti IL-23: preliminary data of a real-life 16-week retrospective study. Dermatol Ther. 2020 Nov;33(6):e14144.
   PubMed Web of Science ®Google Scholar